Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Items 101–200 of 892
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“AAV serotype 2 is the prototype vector and has been extensively tested for its safety in pre-clinical and clinical studies [7].”
BackgroundEngineering the AAV capsid to optimize vector–host-interactions
Büning, H., Huber, A., Zhang, L. N., Meumann, N., & Hacker, U. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.002 · Cited by 127
Gene therapy enters the pharma market: The short story of a long journey
Büning, H. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202291 · Cited by 114
“Thus, besides gene transfer into skeletal muscle as with Glybera, AAV vectors are tested in liver-, lung-, heart-, eye- and central nervous system-directed human clinical trials (Jessup et al, 2011; Mingozzi & High, 2011; Nathwani et al, 2011).”
BackgroundInfluentialSorrentino, N. C., D'Orsi, L., Sambri, I., Nusco, E., Monaco, C., Spampanato, C., Polishchuk, E., Saccone, P., De Leonibus, E., Ballabio, A., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202083 · Cited by 113
“The most effective for therapeutic approaches are those based on helper-dependent adenovirus (HDAd) or on AAV vectors with high liver tropism (serotype 2/8) (Brunetti-Pierri & Ng, 2011; Mingozzi & High, 2011).”
Mingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
Self-citationPompe Disease: New Developments in an Old Lysosomal Storage Disorder
Meena, N. K., & Raben, N. (2020) · Biomolecules · doi:10.3390/biom10091339 · Cited by 128
“The unique immunologic properties of the liver allow for the induction of immune tolerance to foreign antigens through a regulatory T-cell mediated mechanism (reviewed in [136]).”
BackgroundTargeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer
Li, Y., Chen, Z.-K., Duan, X., Zhang, H., Xiao, B.-L., Wang, K.-M., & Chen, G. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00856-3 · Cited by 117
Sharpening the Molecular Scissors: Advances in Gene-Editing Technology
Broeders, M., Herrero-Hernandez, P., Ernst, M. P. T., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2019) · iScience · doi:10.1016/j.isci.2019.100789 · Cited by 127
“In addition, immune responses to viral-based vectors such as AAV are known for their capacity to neutralize the therapy, including an induction of a cytotoxic T cell response that eliminates cells that have been targeted by the AAV vector (Mingozzi and High, 2011, 2013).”
BackgroundPloquin, A., Szécsi, J., Mathieu, C., Guillaume, V., Barateau, V., Ong, K. C., Wong, K. T., Cosset, F., Horvat, B., & Salvetti, A. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis699 · Cited by 117
“First, AAV vectors are derived from a nonpathogenic virus, and their lack of toxicity has been documented in several preclinical and clinical studies [18, 42].”
BackgroundEarley, L. F., Powers, J. M., Adachi, K., Baumgart, J. T., Meyer, N. L., Xie, Q., Chapman, M. S., & Nakai, H. (2017) · Journal of Virology · doi:10.1128/jvi.01980-16 · Cited by 108
Emerging concepts in the therapy of mitochondrial disease
Viscomi, C., Bottani, E., & Zeviani, M. (2015) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2015.03.001 · Cited by 107
“AAVs belong to the parvoviridae family, which are not associated with any disease in humans or animals, and remain episomic in the cells for prolonged time, thus reducing the risk of insertional mutagenesis [94].”
BackgroundMcLean, J. R., Smith, G. A., Rocha, E. M., Hayes, M. A., Beagan, J. A., Hallett, P. J., & Isacson, O. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.05.044 · Cited by 110
Hakim, C. H., Wasala, N. B., Pan, X., Kodippili, K., Yue, Y., Zhang, K., Yao, G., Haffner, B., Duan, S. X., Ramos, J., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.06.006 · Cited by 110
“Encouragingly, AAV gene therapy has resulted in unequivocal clinical successes in treating other inherited diseases such as Leber congenital amaurosis, hemophilia, and spinal muscular atrophy.(5,6)”
BackgroundUse of Ionic Liquids in Protein and DNA Chemistry
Shukla, S. K., & Mikkola, J. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.598662 · Cited by 116
Microfluidic Cell Stretching for Highly Effective Gene Delivery into Hard-to-Transfect Primary Cells
Hur, J., Park, I., Lim, K. M., Doh, J., Cho, S., & Chung, A. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c05169 · Cited by 108
Logan, G. J., Dane, A. P., Hallwirth, C. V., Smyth, C. M., Wilkie, E. E., Amaya, A. K., Zhu, E., Khandekar, N., Ginn, S. L., Liao, S. H. Y., et al. (2017) · Nature Genetics · doi:10.1038/ng.3893 · Cited by 113
Virus-like nanoparticles as a novel delivery tool in gene therapy
Jeevanandam, J., Pal, K., & Danquah, M. K. (2018) · Biochimie · doi:10.1016/j.biochi.2018.11.001 · Cited by 108
Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
Eichhoff, A. M., Börner, K., Albrecht, B., Schäfer, W., Baum, N., Haag, F., Körbelin, J., Trepel, M., Braren, I., Grimm, D., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.003 · Cited by 106
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 113
“Some therapies have been approved for clinical applications.(471) An important advantage of the AAV vector is its tissue tropism.”
BackgroundInduction of hepatocellular carcinoma by in vivo gene targeting
Wang, P.-R., Xu, M., Toffanin, S., Li, Y., Llovet, J. M., & Russell, D. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117032109 · Cited by 105
“Several ongoing or planned clinical trials involve the delivery of AAV vectors to the liver (43, 45), and future genetargeting experiments could help identify the safest promoter/ enhancer elements to be used in these types of trials.”
BackgroundExposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104
Self-citationCarrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 109
Ruzo, A., Marcó, S., García, M., Villacampa, P., Ribera, A., Ayuso, E., Maggioni, L., Mingozzi, F., Haurigot, V., & Bosch, F. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.029 · Cited by 104
“Adeno-associated vectors (AAV) have proven highly ef-ficient in transducing post-mitotic cells in a wide range of tissues, including CNS and liver, resulting in long-lasting transgene expression (Mingozzi et al. , 2011b; Nathwani et al. , 2011).”
Self-citationShen, S., Horowitz, E. D., Troupes, A. N., Brown, S. M., Pulicherla, N., Samulski, R. J., Agbandje-McKenna, M., & Asokan, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.482380 · Cited by 104
Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice
Cantore, A., Nair, N., Della Valle, P., Di Matteo, M., Màtrai, J., Sanvito, F., Brombin, C., Di Serio, C., D'Angelo, A., Chuah, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-432591 · Cited by 101
AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria
Richards, D. Y., Winn, S. R., Dudley, S., Nygaard, S. C., Mighell, T. L., Grompe, M., & Harding, C. O. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.004 · Cited by 110
Approved and marketed nanoparticles for disease targeting and applications in COVID-19
Abdellatif, A. A. H., & Alsowinea, A. F. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0115 · Cited by 115
Capsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100
Self-citationAAV Vectors Vaccines Against Infectious Diseases
Nieto, K., & Salvetti, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00005 · Cited by 100
“Accordingly, several preclinical and clinical gene therapy trials have demonstrated their favorable safety profile (5, 6) .”
BackgroundDevelopment of hybrid viral vectors for gene therapy
Huang, S., & Kamihira, M. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.10.001 · Cited by 111
MiRNA inhibition in tissue engineering and regenerative medicine
Beavers, K. R., Nelson, C. E., & Duvall, C. L. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.006 · Cited by 107
“7 kb), complex to prepare recombinantly, and comprised of AAV viral capsid proteins that can be immunogenic [96].”
BackgroundA Precise Chemical Strategy To Alter the Receptor Specificity of the Adeno‐Associated Virus
Kelemen, R. E., Mukherjee, R., Cao, X., Erickson, S. B., Zheng, Y., & Chatterjee, A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604067 · Cited by 101
The potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 98
“Currently, rAAV vectors are being evaluated in Phase I/II clinical trials for gene therapy of a number of diseases such as Pompe disease [19], cystic fibrosis, a-1 anti-trypsin deficiency, Parkinson’s disease, Batten’s disease, muscular dystrophy, Leber’s congenital amaurosis (LCA) and hemophilia [20].”
Aslanidi, G. V., Rivers, A. E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., & Srivastava, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059142 · Cited by 95
“The requirements for sufficient amounts of the vector pose a production challenge, as well as the risk of initiating the host immune response to the vector [6,7,8].”
BackgroundStructural insights into adeno-associated virus serotype 5
Govindasamy, L., DiMattia, M. A., Gurda, B. L., Halder, S., McKenna, R., Chiorini, J. A., Muzyczka, N., Zolotukhin, S., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.00867-13 · Cited by 95
“Recombinant adeno-associated viruses (rAAVs) are promising viral vectors for gene delivery applications (1, 2).”
BackgroundSmad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Winbanks, C. E., Murphy, K. T., Bernardo, B. C., Qian, H., Liu, Y., Sepulveda, P. V., Beyer, C., Hagg, A., Thomson, R. E., Chen, J. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4976 · Cited by 95
Myotonic dystrophy mouse models: towards rational therapy development
Gomes-Pereira, M., Cooper, T. A., & Gourdon, G. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.004 · Cited by 109
“Efficient systemic AAV delivery in neuromuscular disorders is currently being optimised [83].”
BackgroundRosas, L. E., Grieves, J. L., Zaraspe, K., La Perle, K. M., Fu, H., & McCarty, D. M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.197 · Cited by 96
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
Self-citationNew Directions in Nicotine Vaccine Design and Use
Pentel, P. R., & LeSage, M. G. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00014-7 · Cited by 101
“Gene transfer An emerging approach that bypasses the need for either active or passive immunization is the administration of viral vectors containing genes for the expression of drug-specific antibody (Brimijoin, Shen, Orson, & Kosten, 2013; Mingozzi & High, 2011).”
BackgroundXia, Y., He, J., Zhang, H., Wang, H., Tetz, G. V., Maguire, C. A., Wang, Y., Onuma, A. E., Genkin, D. D., Tetz, V., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12787 · Cited by 98
Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8
Gurda, B. L., Raupp, C., Popa-Wagner, R., Naumer, M., Olson, N. H., Ng, R., McKenna, R., Baker, T. S., Kleinschmidt, J. A., & Agbandje-McKenna, M. (2012) · Journal of Virology · doi:10.1128/jvi.00218-12 · Cited by 93
Chemical modification of the adeno-associated virus capsid to improve gene delivery
Mével, M., Bouzelha, M., Leray, A., Pacouret, S., Guilbaud, M., Penaud-Budloo, M., Alvarez-Dorta, D., Dubreil, L., Gouin, S. G., Combal, J. P., et al. (2020) · Chemical Science · doi:10.1039/c9sc04189c · Cited by 92
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
BackgroundCFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes
Steines, B., Dickey, D. D., Bergen, J., Excoffon, K. J. D. A., Weinstein, J. R., Li, X., Yan, Z., Alaiwa, M. H. A., Shah, V. S., Bouzek, D. C., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88728 · Cited by 92
Bouazzaoui, A., Abdellatif, A. A. H., Al-Allaf, F. A., Bogari, N. M., Al-Dehlawi, S., & Qari, S. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020140 · Cited by 98
A Targeted and Stable Polymeric Nanoformulation Enhances Systemic Delivery of mRNA to Tumors
Chen, Q., Qi, R., Chen, X., Yang, X., Wu, S., Xiao, H., & Dong, W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.006 · Cited by 91
Understanding AAV vector immunogenicity: from particle to patient
Dhungel, B. P., Winburn, I. C., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024) · Theranostics · doi:10.7150/thno.89380 · Cited by 101
“Apart from NAbs [6, 14], memory B cells and T cells are also generated due to natural AAV infection that can be re-activated on subsequent exposure to rAAV vectors [42, 73].”
BackgroundGabriel, N., Hareendran, S., Sen, D., Gadkari, R. A., Sudha, G., Selot, R., Hussain, M., Dhaksnamoorthy, R., Samuel, R., Srinivasan, N., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.194 · Cited by 90
“Recombinant adeno-associated viral (AAV) vectorsbased on serotype 2 have been used successfully for in vivo gene transfer in numerous preclinical animal models (Mingozzi and High, 2011).”
MethodArimura, S., Okada, T., Tezuka, T., Chiyo, T., Kasahara, Y., Yoshimura, T., Motomura, M., Yoshida, N., Beeson, D., Takeda, S., et al. (2014) · Science · doi:10.1126/science.1250744 · Cited by 92
Körbelin, J., Sieber, T., Michelfelder, S., Lunding, L., Spies, E., Hunger, A., Alawi, M., Rapti, K., Indenbirken, D., Müller, O. J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.62 · Cited by 87
Jimenez, V., Muñoz, S., Casana, E., Mallol, C., Elias, I., Jambrina, C., Ribera, A., Ferre, T., Franckhauser, S., & Bosch, F. (2013) · Diabetes · doi:10.2337/db13-0311 · Cited by 88
“Adeno-associated viral (AAV) vectors have emerged as one of the vectors of choice for many gene transfer applications in vivo because of their low immunogenicity and excellent safety profile (24).”
BackgroundInfluentialBortolussi, G., Zentillin, L., Vaníkova, J., Bockor, L., Bellarosa, C., Mancarella, A., Vianello, E., Tiribelli, C., Giacca, M., Vitek, L., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.233 · Cited by 85
“Because of these favorable characteristics, it is not surprising that several of the clinical trials for liver metabolic diseases performed to date have entailed intramuscular gene delivery (Mingozzi and High, 2011).”
BackgroundRocca, C. J., Ur, S. N., Harrison, F., & Cherqui, S. (2014) · Gene Therapy · doi:10.1038/gt.2014.35 · Cited by 92
Rogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85
State-of-the-art human gene therapy: part I. Gene delivery technologies.
Wang, D., & Gao, G. (2014) · PubMed · Cited by 115
Bottani, E., Lamperti, C., Prigione, A., Tiranti, V., Persico, N., & Brunetti, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111083 · Cited by 94
“The mitochondrial uptake process was termed mitochondrial augmentation and is currently proposed for Kearns–Sayre syndrome (KSS) and Pearson Syndrome.”
BackgroundMethodInfluentialGene therapy for haemophilia: a long and winding road
High, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04369.x · Cited by 86
Self-citationCharacterization of AAV vector particle stability at the single-capsid level
Bernaud, J., Rossi, A., Fis, A., Gardette, L., Aillot, L., Büning, H., Castelnovo, M., Salvetti, A., & Faivre-Moskalenko, C. (2018) · Journal of Biological Physics · doi:10.1007/s10867-018-9488-5 · Cited by 83
“Adeno-associated virus (AAV) is a nonpathogenic parvovirus that has emerged as one of the most popular tools for in vivo gene transfer in particular gene therapy [1].”
BackgroundCellular Deformations Induced by Conical Silicon Nanowire Arrays Facilitate Gene Delivery
Chen, Y., Aslanoglou, S., Gervinskas, G., Abdelmaksoud, H. H., Voelcker, N. H., & Elnathan, R. (2019) · Small · doi:10.1002/smll.201904819 · Cited by 87
Nair, N., Rincon, M. Y., Evens, H., Sarcar, S., Dastidar, S., Samara-Kuko, E., Ghandeharian, O., Man Viecelli, H., Thöny, B., De Bleser, P., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534032 · Cited by 84
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Wright, J. F. (2021) · Biotechnology Journal · doi:10.1002/biot.202000022 · Cited by 82
Luo, M., Lee, L. K. C., Peng, B., Choi, C. H. J., Tong, W. Y., & Voelcker, N. H. (2022) · Advanced Science · doi:10.1002/advs.202201740 · Cited by 92
Chhabra, A., Bashirians, G., Petropoulos, C. J., Wrin, T., Paliwal, Y., Henstock, P. V., Somanathan, S., Pereira, C. D. F., Winburn, I. C., & Rasko, J. E. J. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101273 · Cited by 92
Martinez-Navio, J. M., Fuchs, S. P., Pedreño-López, S., Rakasz, E. G., Gao, G., & Desrosiers, R. C. (2016) · Molecular Therapy · doi:10.1038/mt.2015.191 · Cited by 81
Testing thousands of nanoparticles in vivo using DNA barcodes
Lokugamage, M. P., Sago, C. D., & Dahlman, J. E. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.001 · Cited by 83
Liver Soluble Epoxide Hydrolase Regulates Behavioral and Cellular Effects of Chronic Stress
Qin, X.-H., Wu, Z., Dong, J.-H., Zeng, Y.-N., Xiong, W.-C., Liu, C., Wang, M.-Y., Zhu, M.-Z., Chen, W.-J., Zhang, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.006 · Cited by 80
Zhang, T., Huang, Y., Ma, X., Gong, N., Liu, X., Liu, L., Ye, X., Hu, B., Li, C., Tian, J.-H., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02553 · Cited by 80
dCas9-based gene editing for cleavage-free genomic knock-in of long sequences
Wang, C., Qu, Y., Cheng, J. K. W., Hughes, N. W., Zhang, Q., Wang, M., & Cong, L. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00836-1 · Cited by 90
“This allowed us to fit the dSaCas9-mSSAP into a single AAV and employ a >=4kb donor AAV for long-sequence editing (Fig.”
InfluentialChuah, J., Matsugami, A., Hayashi, F., & Numata, K. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01056 · Cited by 83
Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo
Zhang, Y.-H., Wang, Y., Yusufali, A. H., Ashby, F. J., Zhang, D., Yin, Z.-F., Aslanidi, G., Srivastava, A., Ling, C., & Ling, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60057-1 · Cited by 79
Mouse γ-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Wang, Q., Zhuang, P., Huang, H., Li, L., Liu, L., Webber, H. C., Dalal, R., Siew, L., Fligor, C. M., Chang, K.-C., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0102-20.2020 · Cited by 77
“The success of adeno-associated virus (AAV)-mediated gene replacement in treating inherited retinal disease (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008, 2009; Busskamp et al., 2010; Gorbatyuk et al., 2010; Mingozzi and High, 2011; Boye et al., 2013; Smalley, 2017) makes RGC-specific gene exp…”
BackgroundSong, L., Kauss, M. A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G. R., Rivers, A. E., Aslanidi, G. V., Ling, C., et al. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.04.003 · Cited by 80
“The safety as well as clinical efficacy of recombinant vectors based on a non-pathogenic human virus, the adeno-associated virus 2 (AAV2) has attracted attention [2, 3].”
Treatment of Diabetes and Long-Term Survival After Insulin and Glucokinase Gene Therapy
Callejas, D., Mann, C. J., Ayuso, E., Lage, R., Grifoll, I., Roca, C., Andaluz, A., Fernández, R. R. D. G. I., Montané, J., MUÑOZ, S. A., et al. (2013) · Diabetes · doi:10.2337/db12-1113 · Cited by 95
“Preclinical studies have shown that AAV-mediated gene transfer results in long-term gene expression in small and large animal models (10).”
BackgroundSelf-citationLovric, J., Mano, M., Zentilin, L., Eulalio, A., Zacchigna, S., & Giacca, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.144 · Cited by 77
Ayers, J. I., Fromholt, S., Sinyavskaya, O., Siemienski, Z., Rosario, A. M., Li, A., Crosby, K. W., Cruz, P. E., DiNunno, N. M., Janus, C., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.180 · Cited by 76
Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
“Wild-type AAV is nonpathogenic and recombinant AAV vector is weakly immunogenic (Mays and Wilson, 2011; Mingozzi and High, 2011a).”
rAAV-compatible MiniPromoters for restricted expression in the brain and eye
de Leeuw, C. N., Korecki, A. J., Berry, G. E., Hickmott, J. W., Lam, S. L., Lengyell, T. C., Bonaguro, R. J., Borretta, L. J., Chopra, V., Chou, A. Y., et al. (2016) · Molecular Brain · doi:10.1186/s13041-016-0232-4 · Cited by 76
“CNS [11–17].”
Duchenne Muscular Dystrophy Gene Therapy in the Canine Model
Duan, D. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.006 · Cited by 88
“AAV-based gene replacement therapy has shown unprecedented clinical success in treating inherited diseases.(62) However, there is a major limiting factor to use AAV in DMD gene therapy.”
Next stop for the CRISPR revolution: RNA‐guided epigenetic regulators
Vora, S., Tuttle, M., Cheng, J., & Church, G. (2016) · The FEBS Journal · doi:10.1111/febs.13768 · Cited by 77
Parambi, D. G. T., Alharbi, K. S., Kumar, R., Harilal, S., Batiha, G. E., Martins, N. A., Hendawy, O. M., Musa, A., Panda, D. S., & Mathew, B. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02555-y · Cited by 82
Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy
Gong, Y., Mu, D., Prabhakar, S., Moser, A., Musolino, P., Ren, J., Breakefield, X. O., Maguire, C. A., & Eichler, F. S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.6 · Cited by 74
Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver
Viecelli, H. M., Harbottle, R. P., Wong, S. P., Schlegel, A., Chuah, M. K., VandenDriessche, T., Harding, C. O., & Thöny, B. (2014) · Hepatology · doi:10.1002/hep.27104 · Cited by 78
“Predictions of the immune response in humans following viral vector administration based on the innate and antigen-dependent immune responses seen in animal models have not been accurate.(12) This is likely because the diversity of the immune system between mice and humans is generally underestimated, which makes extr…”
A new generation of human artificial chromosomes for functional genomics and gene therapy
Kouprina, N., Earnshaw, W. C., Masumoto, H., & Larionov, V. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1113-3 · Cited by 81
Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
Cruickshanks, N. A., Zhang, Y., Yuan, F., Pahuski, M., Gibert, M. K., & Abounader, R. (2017) · Cancers · doi:10.3390/cancers9070087 · Cited by 74
“Other delivery mechanisms available include, adeno-associated virus [93], polymeric brain-penetrating nano-particles [94] and mesenchymal stem cells [95,96].”
BackgroundAcoustically-mediated intracellular delivery
Ramesan, S., Rezk, A. R., Dekiwadia, C. D., Cortez‐Jugo, C., & Yeo, L. Y. (2018) · Nanoscale · doi:10.1039/c8nr02898b · Cited by 80
Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9
Afolabi, L. O., Adeshakin, A. O., Sani, M. M., Bi, J., & Wan, X. (2019) · Immunology · doi:10.1111/imm.13094 · Cited by 83
Chicoine, L. G., Rodino-Klapac, L. R., Shao, G., Xu, R., Bremer, W. G., Camboni, M., Golden, B., Montgomery, C. L., Shontz, K., Heller, K. N., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.246 · Cited by 73
Milani, M., Annoni, A., Bartolaccini, S., Biffi, M., Russo, F., Di Tomaso, T., Raimondi, A., Lengler, J., Holmes, M. C., Scheiflinger, F., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708148 · Cited by 72
“Underlying this success is the development of improved gene transfer vectors (Kay, 2011; Mingozzi & High, 2011; Nathwani et al, 2014).”
BackgroundRetinal Cyclic Nucleotide-Gated Channels: From Pathophysiology to Therapy
Michalakis, S., Bećirović, E., & Biel, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030749 · Cited by 75
Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors
Puhl, D. L., D’Amato, A. R., & Gilbert, R. J. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.05.024 · Cited by 81
Ex vivo gene therapy for the treatment of neurological disorders
Gowing, G., Svendsen, S. P., & Svendsen, C. N. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.11.003 · Cited by 88
Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus
Liu, Y., Zhao, M., Gong, M., Xu, Y., Xie, C., Deng, H., Li, X., Wu, H., & Wang, Z. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.02.011 · Cited by 75
Catalytic RNA, ribozyme, and its applications in synthetic biology
Park, S. V., Yang, J., Jo, H., Kang, B., Oh, S. S., & Jung, G. Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107452 · Cited by 82
Lin, S., Yin, S., Shi, J., Yang, G., Wen, X., Zhang, W., Zhou, M., & Jiang, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.03.024 · Cited by 89
“Nevertheless, translating these strategies from the bench to the bed side remains challenging due to their limitations, including safety and ethical concerns of gene editing [10], the use of GFs without regulatory approval [11], and complicated manufacturing procedures [9].”
BackgroundRonzitti, G., Bortolussi, G., van Dijk, R., Collaud, F., Charles, S., Leborgne, C., Vidal, P., Martin, S., Gjata, B., Sola, M. S., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.49 · Cited by 69
Self-citationDifferent Methods of Delivering CRISPR/Cas9 Into Cells
Chandrasekaran, A. P., Song, M., Kim, K.-S., & Ramakrishna, S. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.05.001 · Cited by 81
AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations
Pacouret, S., Bouzelha, M., Shelke, R., Andres-Mateos, E., Xiao, R., Maurer, A., Mevel, M., Turunen, H., Barungi, T., Penaud-Budloo, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.001 · Cited by 69
Majowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J., Konstantinova, P., & Ferreira, V. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2712 · Cited by 71
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.